Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Sep 15, 2016Discovery innovation unit of 90 scientists at dedicated research facility to use human genetics and related data to develop novel, targeted medicines for dementia and oncology
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., has announced the launch of the Eisai Andover innovative Medicines (AiM) Institute, a discovery innovation unit within the...
- Sep 14, 2016
Eisai Inc. today announced that new data presented at the 12th European Congress on Epileptology (ECE) showed that long-term adjunctive use of FYCOMPA® (perampanel) CIII for up to two and a half...
- Jul 28, 2016Child Neurology Foundation Initiative Provides Guidance for Pediatric Neurology Patients
The Child Neurology Foundation (CNF) announced today that a consensus statement addressing the role of the neurologist in transitioning children to the adult healthcare system has been published...
Jul 19, 2016Once-a-Day Tablet Offers Millions of Americans a New Option to Address Chronic Weight ManagementEisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for BELVIQ XR® (lorcaserin...
- Jul 14, 2016Eisai and Arena Pharmaceuticals Announce Regulatory Approval of VENESPRI® (lorcaserin HCl) in MexicoFirst Country in Latin America to Approve lorcaserin
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) has granted regulatory approval of the...
